paracentesis-induced circulatory dysfunction acute decompensation or acute-on-chronic liver failure Decompensated cirrhosis, acute-on-chronic liver failure, portal hypertension, acute kidney injury, ascites
Conditions
Interventions
1. Patients who were admitted with an acute decompensation/ACLF and have ascites grade 3.
2. 20% human albumin for replacement 4 gm/L of ascites drainage ,1. Patients who were admitted with an acute d
Experimental Drug,No Intervention No treatment
20% Albumin,No medication
Sponsors
Faculty of Medicine, Prince of Songkla University
Thai Association for the Study of the Liver,The Royal College of Physicians of Thailand,Fundamental Fund, Prince of Songkla University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-80 2. Chronic hepatitis disease with acute decompensation or acute-on-chronic liver failure 3. Grade 3 ascites with abdominal distension or respiratory discomfort 4. Ascites release less than 5 liters
Exclusion criteria
Exclusion criteria: 1. Disseminated intravascular coagulation 2. Hepatocellular carcinoma, BCLC-D before this treatment 3. Active pulmonary edema or active congestive heart failure on the date of enrollment 4. Serum creatinine > 1.5 mg/dL on the date of enrollment or chronic kidney disease (renal replacement therapy) 5. Gastrointestinal bleeding that cannot be stopped 6. Hemodynamic instability on the date of enrollment (defined as a mean arterial pressure [MAP] of <65 mmHg or escalating doses of vasopressor/inotropic agents required to maintain a MAP value of >65 mmHg within 24 hours) 7. Pregnant 8. The patients has a history of allergy to albumin 9. The patients does not wish to participate in the research project 10. Patients whose life expectancy is through to be less than 2 weeks by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare patient that has PCCD condition and AKI or hyponatremia between patient that recieved albumin and placebo Beginning of the study and day6 Lab automachine | — |
Secondary
| Measure | Time frame |
|---|---|
| survival in hospital or survival in 28 days between patient that recieved albumin and placebo Day before discharge from hospital and day28 Questionaire | — |
Countries
Thailand
Contacts
Public ContactPimsiri Sripongpun
Faculty of Medicine,Prince of songkla University
Outcome results
None listed